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Abstract
Purpose The purpose of the study was to
study the effect of an organic light-emitting
diode sleep mask on daytime alertness,
wellbeing, and retinal structure/function in
healthy volunteers and in diabetic macular
oedema (DMO).
Patients and methods Healthy volunteers in
two groups, 18–30 yrs (A), 50–70 yrs (B) and
people with DMO (C) wore masks (504 nm
wavelength; 80 cd/m2 luminance; ≤ 8 h)
nightly for 3 months followed by a 1-month
recovery period. Changes from baseline were
measured for (means): psychomotor vigilance
task (PVT) (number of lapses (NL), response
time (RT)), sleep, depression, psychological
wellbeing (PW), visual acuity, contrast
sensitivity, colour, electrophysiology,
microperimetry, and retinal thickness
on OCT.
Results Of 60 participants, 16 (27%)
withdrew, 8 (13%) before month 1, due to
sleep disturbances and mask intolerance.
About 36/55 (65%) who continued beyond
month 1 reported ≥ 1 adverse event. At month
3 mean PVT worsened in Group A (RT
(7.65%, Po0.001), NL (43.3%, P= 0.005)) and
mean PW worsened in all groups (A 28.0%,
P= 0.01, B 21.2%, P= 0.03, C 12.8%, Po0.05).
No other clinically signiﬁcant safety signal
was detected. Cysts reduced/resolved in the
OCT subﬁeld of maximal pathology in 67%
Group C eyes. Thinning was greater at 3 and
4 months for greater baseline thickness
(central subﬁeld Po0.001, maximal Po0.05).
Conclusion Sleep masks showed no major
safety signal apart from a small impairment
of daytime alertness and a moderate effect on
wellbeing. Masks were acceptable apart from
in some healthy participants. Preliminary data
suggest a beneﬁcial effect on retinal thickness
in DMO. This novel therapeutic approach is
ready for large clinical trials.
Eye advance online publication, 16 December
2016;. doi:10.1038/eye.2016.259
Introduction
The increased oxygen demand in the outer retina
in the dark, due mostly to the 140 million rods that
double their oxygen intake in the dark adapted
eye during sleep, may contribute to intraretinal
hypoxic drive in a range of retinal vasculopathies
including diabetic retinopathy (DR) leading to
upregulation of the VEGF pathway.1 If dark
adaptation could be prevented or reduced, the
reduction of intraretinal hypoxia may diminish the
progression of DR and its complications.2
Light is a novel approach to modifying the
hypoxia associated with dark adaptation.3,4
Sleeping in an illuminated environment with
light delivered through the closed lid has been
tested in two small studies as a potential therapy
for diabetic maculopathy.5,6 Before light therapy
can be more widely considered robust evidence
on safety is required.
We developed a sleep mask containing a thin,
ﬂexible, organic light-emitting diode (OLED) to
suppress dark adaptation therapeutically. We
investigated if long-term nocturnal light
exposure with this device could lead to sleep
deprivation and effects on daytime alertness,
psychological wellbeing, and retinal structure
and function. We also studied safety in people
with diabetic macular oedema (DMO).
Materials and methods
Healthy adult volunteers with good general
health from two age groups (Group A: aged
18–30 years; Group B: aged 50–70 years) were
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consented and recruited into a single-centre, prospective,
longitudinal, non-commercial, interventional safety study
with a 3-month dosing period followed by a 1-month post
dosing assessment.
Key exclusion criteria were: disease that might affect
the blood–retina barrier, unstable ﬁxation on
microperimetry, history of sleep disorders, depression or
psychiatric disorders, psychomotor vigilance task (PVT),
number of lapses (NL) ≥ 17 (see below), and use of
psychoactive drugs.
The study complied with the Declaration of Helsinki
was approved by the National Research Ethics
Committee (13/WM/0011) and the Institutional
Technical Devices Committee as a device study with a
CE-marked device. It complied with the Declaration of
Helsinki.
People attending for monitoring of DMO were assessed
(Group C). Additional inclusion criteria: best corrected
visual acuity (BCVA) ≥ 73 ETDRS letters, retinopathy
≤ETDRS grade 47, DMO meeting deﬁnition of clinically
signiﬁcant macular oedema, mean subﬁeld thickness ≥ 2
SD in any central ﬁve OCT subﬁelds.
OLED sleep masks developed by Polyphotonix Medical
Ltd (Figure 1) comprised a soft cushioned fabric mask
containing a plastic ‘Pod’ containing the light sources
emitting light into the eyes through closed lids. The OLED
spectrum with a peak of 504 nm was designed to closely
match the scotopic response curve for selective activation
of rods and to deliver a light intensity of 2 scotopic
Trolands at the retina to suppress dark adaptation.6
Touching a capacitive sensor activated the mask for a
maximum 8 h controlled by an internal clock with
delivered dose recorded by internal sensors (hours of
wear/month).
After training, participants were instructed to wear the
mask each night for 3 months and record sleep times and
experiences in a diary. Participants attended monthly for
4 months and were replaced if they withdrew before
completing the month 1 visit. A small honorarium and
reimbursement of expenses were provided.
Study procedures (all visits)
The PVT measured loss of concentration and alertness
caused by sleep deprivation as increasing response time
(ms) (PVT-RT) and NL (failure to respond) (PVT-NL).
Using normative data we derived upper limits of normal
(mean+2 SD): NL≤ 16; RT≤ 459, ≤ 359.7 The Karolinska
Sleepiness Scale (KSS) (range 1–9 (worst))8 and the
Pittsburgh Sleep Quality Index (PSQI) (range 0–21
(worst))9 questionnaires assessed level of sleepiness and
sleep quality. PVT-NL, PVT-RT, KSS, and PSQI served as
co-primary outcomes.
Self-reported symptoms of depression were assessed
using the Centre for Epidemiologic Studies Depression
scale (CESD) (abnormal ≥ 16)10 and psychological
wellbeing using the General Health Questionnaire
(GHQ12) (range 0–36, 415 evidence of distress, 420
severe distress).11
The following were also assessed: medical and ocular
history, ophthalmological examination, BCVA (ETDRS
letters at 1 m), Pelli Robson contrast sensitivity (CS),
colour vision Cambridge colour test ((CCT); Cambridge
Research Systems (Rochester, Kent, UK), normal
thresholds o100 × 10− 4 u'v' protan and deutan,
o150× 10− 4 u'v' tritan12) 19-segment multifocal
electroretinogram13 (mfERG, Roland Retiscan,
Brandenburg an der Havel, Germany), electrooculogram
(EOG), microperimetry (MP, Nidek MP1, Padova, Italy),
mean central subﬁeld thickness on spectral domain
optical coherence tomography (SD-OCT). For Group C
mean thickness was also recorded for subﬁeld with
maximal OCT pathology with a qualitative assessment of
response to therapy.
Adverse events including discomfort, sleep
disturbance, mood alterations, daytime wakefulness, and
Figure 1 Principal components of OLED sleep mask. Left panel: plastic pod containing OLED light source delivering light at 504 nm
peak for a maximum of 8 h with dose delivery sensor. Right panel: soft cushioned fabric mask that houses the plastic pod.
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reasons for withdrawal were recorded and reviewed
independently for relatedness (SPH, TG).
Statistical analysis
Groups of 20 were selected for the healthy cohort based
on accepted guidance for paired t-tests in the lack of
previously published data. Demographics and baseline
variables were compared across groups using two-sided
2-sample t-test where variances were equal; if the unequal
variances t-test was used, then this was reported in the
results.
Analysis used STATA 13.1 (StataCorp LP, Timberlake,
Richmond, UK) with log-transformations for non-normal
distributions and linear regression where the dependent
variable was change from baseline to 3 (primary analysis)
and 4 months with hours of mask wear as a covariate
(centred by average). The resultant regression intercept
represented the mean change from baseline to month 3 (or
4) for the average amount of mask wear.
A 2-step method adjusted values of α for multiple
comparisons of change of our four co-primary variables
only: (1) standard Bonferroni for a family-wise error rate
(change from baseline to month 3 in each of four co-
primary outcomes) equivalent to 0.05: 0.05/4= 0.013 (2)
Holm–Bonferroni to compare ordered P-values for the
two hypotheses in each group (Groups A and B) giving
corrected signiﬁcance levels of 0.013 and 0.0063. P-values
are presented uncorrected and interpreted against these
revised values of α.
Results
About 45 healthy volunteers were recruited, 21 Group A
(18–30 years) and 24 Group B (50–70 years), and 15
participants to Group C. Patient demographics and
baseline variables are presented in Supplementary
Table 1. All daytime alertness, psychological wellbeing,
and retinal structure/function variables were worse in
Group C compared with Group B (similar mean ages),
signiﬁcant for CCT (2-sample t-test with unequal
variances: protan and deutan Po0.01, tritan Po0.001)
and PSQI (Tukey pairwise, P= 0.05).
Of 60 recruited participants, 8 withdrew before month 1
and were replaced. Eight withdrew after completing
month 1. Numbers completing all study visits were: A 17,
B 17, and C 12. Reasons for withdrawal are listed in
Table 1. Light intolerance and sleep disturbance were
cited by one participant in Group A and ﬁve in Group B.
Figure 2 shows mean hours of sleep mask wear,
equivalent to exposure to light therapy. Time of mask
wear from baseline to month 3 (mean ± SD) was lower in
Group A (410 ± 125 h) than Groups B (559± 87.4,
Po0.001, ANOVA) and C (495.8± 139.1, P= 0.002). In
Group A mask wear was more variable but stayed stable,
whereas in Group B it improved and became more
consistent with time. On average younger healthy
participants received 56% of the available light dose (with
wider variability) compared with 76% in older
participants (2-sample t-test with unequal variances
Po0.001). Patients with DMO also had a wide variation
in hours worn per month, which dropped off by month 2
(2-sample t-test with unequal variances P= 0.006).
Safety
Tables 2 and 3 show changes in study variables at months
3 and 4 compared with baseline for participants who
Table 1 Reasons given for withdrawal of 16 participants by
study visit
Reported reason for withdrawal Group A Group B Group C
Before month 1
Intolerance of light and sleep disturbances 0 3 0
Unable to attend follow-up 1 0 1
Could not perform study investigations 0 0 1
No reason given 0 1 1
After month 1
Intolerance of light and sleep disturbances 0 2 0
Unrelated medical event 0 0 1
At month 2
Intolerance of light and sleep disturbances 1 0 0
Could not perform study investigations 0 1 0
Unable to attend follow-up 2 0 0
No reason given 0 0 1
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Figure 2 Boxplots for total hours of mask wear in those
participants (Group A n= 17, Group B n= 17, and Group c
n= 12) who completed 3 months of the study. Median is shown
as horizontal line with upper and lower quartile as box, and
range minima and maxima at ends of vertical lines; outliers with
single months with reduced mask wear shown as single points
(patient 29 108 h in month 2, patient 31 138 h in month 3, and
patient 34 129 h in month 3).
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completed 3 months of sleep mask wear (A 17, B 17,
and C 12). At month 3, the PVT-RT deteriorated in both
healthy groups (A 24.39 (7.25%), B 25.39 (7.65%)),
statistically signiﬁcant for Group A (Po0.001). PVT-NL
deteriorated signiﬁcantly in Group A (1.96 (43.27%),
P= 0.005). RT stayed depressed at month 4 whereas
NL recovered. Group C had worse baseline levels of
PVT than Group B but both older age groups
showed no statistically signiﬁcant change during
the study.
Interpreting our secondary outcomes requires some
caution due to multiple comparisons. Psychological
wellbeing (GHQ12) worsened in all the groups at month 3
(A 28.0%, P= 0.01; B 21.2%, P= 0.03; C 12.7%, Po0.05)
with a small but statistically signiﬁcant greater effect with
increasing mask wear.
In older participants there was a consistent
improvement in CCT thresholds at month 3, statistically
signiﬁcant for deutan (13.00 (19.5%) P= 0.01). There were
small increases in BCVA at month 4: Group A +2.44
letters (Po0.001), Group B +1.59 letters (P= 0.025). No
change was detected in Group C at month 3 in BCVA, CS,
mfERG, EOG, or for any other variables in any group. We
detected no clinically important effect on primary or
secondary variables associated with duration of recorded
mask wear apart from GHQ12.
Table 2 Changes in alertness, sleep quality, psychological wellbeing, and ocular function and structure at month 3 in 46 participants
who completed 3 months of sleep mask wear
Group A (n= 17) Group B (n= 17) Group C (n= 12)
Baseline (SD)
range
Change at month 3
(95% CI) P-value
Baseline (SD)
range
Change at month 3
(95% CI) P-value
Baseline (SD)
range
Change at month 3
(95% CI) P-value
PVT-NL (number) 4.53 (4.69)
0–18
1.96 (0.63, 3.64)
0.005a
4.30 (5.44)
0–24
− 0.17 (−1.15, 1.11)
0.75
6.08 (5.42)
1–21
− 0.8 (−1.99, 1.82)
0.93
PVT-RT (ms) 336.41 (36.62)
270.89–418.43
24.39 (13.35, 39.12)
o0.001a
332.10 (50.5)
276.1–456.6
25.39 (6.71, 42.34)
0.02
346.95 (13.37)
208–430
6.93 (−9.67, 23.53)
0.19
KSS (score) 3.41 (1.80)
1–7
0.74 (−0.33, 1.86)
0.16
2.41 (1.12)
1–5
0.47 (−0.16, 1.10)
0.13
2.92 (1.62)
1–7
0.08 (−1.41, 1.58)
0.90
PSQ (score) 2.65 (2.32)
0–8
0.82 (−0.16, 1.81)
0.09
3.60 (2.23)
1–9
0.06 (−1.23, 1.35)
0.92
4.58 (2.87)
1–11
0.5 (−0.57, 1.57)
0.32
CESD (score) 4.30 (3.87)
0–16
1.35 (−0.52, 3.23)
0.15
4.20 (4.50)
0–13
− 0.88 (−3.13, 1.37)
0.42
6.33 (6.23)
0–20
1.25 (−1.92, 4.42)
0.40
GHQ12 (score) 6.71 (2.02)
4–11
1.88 (0.51, 3.25)
0.01
6.94 (2.51)
3–12
1.47 (0.20, 2.74)
0.03
7.83 (2.72)
5–14
1.00 (0.02, 1.94)
0.046
BCVA (letters) 90.65 (3.32)
85–96
1.59 (−0.02, 3.19)
0.05
89.18 (3.28)
83–95
1.17 (−0.10, 2.45)
0.07
85.92 (5.18)
79–93
− 0.33 (−2.37, 1.70)
0.73
CS (letters) 41.29 (1.36)
37–42
0.35 (−0.37, 1.08)
0.32
41.18 (1.51)
36–42
0.17 (−0.64, 0.99)
0.65
35.0 (3.74)
30–41
1.0 (−0.67, 2.67)
0.11
CCT protan (u’v’) 60.29 (19.47)
22–95
− 3.41 (−12.35, 5.52)
0.43
61.56 (14.47)
40–86
− 7.75 (−19.93, 4.43)
0.19
141.64 (89.35)
42–353
− 37.14 (−90.14, 15.85)
0.15
CCT deutan (u’v’) 53.47 (18.57)
26–97
2.59 (−5.69, 10.87)
0.51
66.56 (19.19)
45–122
− 13.00 (−22.73, − 3.27)
0.01
133.25 (99.47)
59–411
− 32.75 (−96.45, 30.95)
0.28
CCT tritan (u’v’) 64.12 (22.51)
33–106
− 2.47 (−16.02, 11.08)
0.70
78.06 (36.58)
29–158
− 4.06 (−28.84, 20.71)
0.73
233.0 (131.55)
34–488
− 46.5 (−129.3, 36.3)
0.24
mfERG amp 1 (μV) 68.98 (16.02)
41.5–108
0.39 (−8.43, 9.21)
0.92
64.25 (12.22)
44.9–88.6
1.45 (−3.99, 6.91)
0.58
56.17 (9.76)
38.2–70.1
0.73 (−7.17, 8.65)
0.84
mfERG lat 1 (ms) 35.81 (2.19)
31.5–40.2
− 1.18 (−2.14, − 0.22)
0.02
36.25 (1.72)
33.4–39.2
− 0.29 (−1.05, 0.48)
0.44
38.18 (2.05)
35.4–41.3
− 0.35 (−1.33, 0.62)
0.44
EOG (light rise ratio) 2.36 (0.40)
1.66–3.00
0.16 (−0.68, 0.99)
0.70
2.22 (0.42)
1.60–3.00
0.19 (−1.08, 1.47)
0.75
2.46 (0.60)
1.7–3.6
− 0.12 (−0.42, 0.18)
0.19
MP1 (dB) 19.45 (1.13)
15.6–20
0.25 (−0.28, 0.78)
0.33
19.41 (1.05)
16.6–20
− 0.06 (−0.73, 0.61)
0.86
13.7 (3.19)
6.6–17.8
1.95 (−0.39, 4.29)
0.09
OCT CST (μm) 274.53 (16.72)
238–308
− 0.53 (−2.60, 1.54)
0.60
286.53 (20.88)
255–319
− 2.82 (−5.62, − 0.02)
0.05
320.50 (35.34)
274–389
− 6.25 (−20.40, 7.90)
0.35
OCT maxST (μm) 365.33 (34.69)
327–439
− 12.00 (−28.80, 4.80)
0.14
Abbreviations: BCVA, best corrected visual acuity; CCT, Cambridge color vision test; CESD, The Centre for Epidemiologic Studies Depression scale; CS,
contrast sensitivity; EOG, electrooculogram; GHQ12, General Health Questionnaire of psychological wellbeing; KSS, Karolinska Sleep Scale; mfERG,
multifocal electroretinogram; MP1, microperimetry; OCT CST, optical coherence tomography mean central subﬁeld thickness; OCT maxST, mean thickness
of OCT subﬁeld with maximal pathology; PSQI, Pittsburgh Sleep Quality Index; PVT-NL, psychomotor vigilance task (PVT) number of lapses; PVT-RT,
PVT response time.
Data are presented as means with SD or 95% conﬁdence intervals, corrected for hours of mask wear. P-values refer to paired t-tests of change in
outcome (month 3 minus baseline), are uncorrected and should be interpreted against adjusted values of α (see text). Levels of P ≤ 0.05 are shown in bold.
aIndicates statistically signiﬁcant co-primary variable.
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About 75% participants in Groups A and B and 40% in
Group C who wore the sleep mask for ≥ 1 month reported
≥ 1 adverse event (Supplementary Table 2). Events were
mostly attributed to the fabric mask housing the ‘Pod’.
One SAE deemed unlikely to be related to the sleep mask
occurred in Group C.
About 40/45 (95%) healthy participants and 13/15
(87%) DMO patients completed sleep diaries during the
dosing period (61% for all 3 months). Thirty-three
reported mask discomfort and slippage. Three
participants (none in Group C) reported the light as an
issue and then only at month 1; all three completed
the study.
DMO
For Group C all measures of retinal function and structure
showed no statistically signiﬁcant improvement or
change with increasing hours of mask wear (Tables 2 and 3);
however there were trends for improvement across all
measures. There was a near signiﬁcant OCT effect for the
ﬁeld of maximal pathology at month 4 (P= 0.07). About
10/15 (67%) showed a reduction/clearance of cysts in the
maximum pathology subﬁeld.
Statistically signiﬁcant greater changes in mean
thicknesses per 1 μm change in baseline thickness were
seen for CST and maxCT at 3 and 4 months: month 3:
Table 3 Changes in alertness, sleep quality, psychological wellbeing, and ocular function and structure 1 month after discontinuing
sleep mask wear in 46 participants who completed 3 months of wear
Group A (n= 17) Group B (n= 17) Group C (n= 12)
Baseline (SD)
range
Change at month 4
(95% CI)
P-value
Baseline (SD)
range
Change at month 4
(95% CI)
P-value
Baseline (SD)
range
Change at month 4
(95% CI)
P-value
PVT-NL (number) 4.53 (4.69)
0–18
0.59 (−0.26, 11.28)
0.07
4.30 (5.44)
0–24
1.39 (−0.95, 5.27)
0.27
6.08 (5.42)
1–21
1.25 (−7.93, 4.43)
0.41
PVT-RT (ms) 336.41 (36.62)
270.89–418.43
28.02 (10.24, 46.70)
0.005
332.10 (50.5)
276.1–456.6
27.66 (10.11, 46.10)
0.01
346.95 (13.37)
208–430
10.03 (−5.70, 25.77)
0.09
KSS (score) 3.41 (1.80)
1–7
0.41 (−0.68, 1.50)
0.44
2.41 (1.12)
1–5
0.29 (−0.33, 0.92)
0.33
2.92 (1.62)
1–7
− 0.58 (−1.81, 0.64)
0.32
PSQ (score) 2.65 (2.32)
0–8
0.12 (−0.73, 0.97)
0.77
3.60 (2.23)
1–9
0.71 (−0.63, 2.04)
0.28
4.58 (2.87)
1–11
0.92 (−0.82, 2.66)
0.27
CESD (score) 4.30 (3.87)
0–16
1.38 (−1.05, 3.80)
0.24
4.20 (4.50)
0–13
0.19 (−2.65, 3.02)
0.88
6.33 (6.23)
0–20
3.67 (−1.19, 8.52)
0.12
GHQ12 (score) 6.71 (2.02)
4–11
0.94 (−0.39, 2.27)
0.15
6.94 (2.51)
3–12
1.06 (−0.79, 2.91)
0.24
7.83 (2.72)
5–14
2.08 (−0.19, 4.36)
0.07
BCVA (letters) 90.65 (3.32)
85–96
2.44 (0.68, 4.20)
0.001
89.18 (3.28)
83–95
1.59 (0.23, 2.95)
0.025
85.92 (5.18)
79–93
0.00 (−2.56, 2.56)
1.00
CS (letters) 41.29 (1.36)
37–42
0.56 (−0.26, 1.39)
0.17
41.18 (1.51)
36–42
0.06 (−0.47, 0.59)
0.82
35.0 (3.74)
30–41
2.57 (0.84, 4.33)
0.01
CCT protan (u’v’) 60.29 (19.47)
22–95
− 8.88 (−9.78, 2.01)
0.10
61.56 (14.47)
40–86
− 2.19 (−14.14, 9.76)
0.70
141.64 (89.35)
42–353
− 37.56 (−95.04, 19.92)
0.18
CCT deutan (u’v’) 53.47 (18.57)
26–97
− 1.29 (−11.68, 9.10)
0.80
66.56 (19.19)
45–122
− 10.00 (−19.14, 2.55)
0.11
133.25 (99.47)
59–411
− 46.17 (−114.1, 21.77)
0.16
CCT tritan (u’v’) 64.12 (22.51)
33–106
− 3.47 (−22.11, 15.16)
0.70
78.06 (36.58)
29–158
0.19 (−18.07, 18.44)
0.98
233.0 (131.55)
34–488
− 54.83 (−125.5, 15.8)
0.12
mfERG amp 1 (μV) 19.45 (1.13)
15.6–20
0.10 (−0.28, 0.48)
0.59
19.41 (1.05)
16.6–20
0.30 (−0.14, 1.14)
0.30
55.73 (9.42)
38.2–70.1
− 2.71 (−10.75, 5.33)
0.47
mfERG lat 1 (ms) 68.98 (16.02)
41.5–108
1.70 (−7.35, 10.75)
0.70
64.25 (12.22)
44.9–88.6
7.81 (0.88, 14.74)
0.03
38.20 (1.95)
35.4–41.3
− 0.72 (−1.94, 0.49)
0.21
MP1 (dB) 35.81 (2.19)
31.5–40.2
− 1.22 (−2.14, − 0.30)
0.01
36.25 (1.72)
33.4–39.2
0.08 (0.84, 1.01)
0.85
13.7 (3.19)
6.6–17.8
2.29 (0.18, 4.41)
0.04
OCT CST (μm) 274.53 (16.72)
238–308
0.24 (−1.41, 1.88)
0.77
286.53 (20.88)
255–319
1.24 (−3.18, 5.65)
0.56
320.50 (35.34)
274–389
− 7.58 (−22.08, 6.91)
0.27
OCT maxST (μm) 365.33 (34.69)
327–439
− 15.58 (−32.93, 1.76)
0.07
Abbreviations: BCVA, best corrected visual acuity; CCT, Cambridge color vision test; CESD, The Centre for Epidemiologic Studies Depression scale; CS,
contrast sensitivity; EOG, electrooculogram; GHQ12, General Health Questionnaire of psychological wellbeing; KSS, Karolinska Sleep Scale; mfERG,
multifocal electroretinogram; MP1, microperimetry; OCT CST, optical coherence tomography mean central subﬁeld thickness; OCT maxST, mean thickness
of OCT subﬁeld with maximal pathology; PSQI, Pittsburgh Sleep Quality Index; PVT-NL, psychomotor vigilance task (PVT) number of lapses; PVT-RT,
PVT response time.
EOG was not recorded at this visit. Data are presented as means with SD or 95% conﬁdence intervals, corrected for hours of mask wear. Data on the effect
of mask wear are also presented as effect of 100 h wear. P-values are uncorrected and shown in bold if ≤ 0.05.
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CST: − 0.77 (−1.03,− 0.53), Po0.001; month 4: CST: − 0.79
(−1.05,− 0.53), Po0.001; maxST: month 3: − 0.44
(−0.87,− 0.02), P= 0.05, month 4: − 0.62 (−0.96,− 0.28),
Po0.01. For the subﬁeld of maximal pathology, for each
10 μm increase in baseline thickness, there was a
corresponding greater reduction of thickness of 4–6 μm.
Discussion
This is the ﬁrst safety study, to our knowledge, of a sleep
mask containing an OLED device designed as a potential
therapy for retinal diseases.
We designed a stimulus aimed at evenly reducing the
rod dark current without stimulating cones. Previous
work has used LED light, which has a narrow spectral
bandwidth and is directional.5,6 Emission from our OLED
was close to Lambertian and homogenous across the
plane of the OLED, ensuring even illumination of the
retina and minimising the effect of eye movement during
sleep. This allowed the brain to adapt to the presence of
the light through Troxler’s fading.14 After attenuation of
the output spectrum by the lid and ocular media, mesopic
retinal illumination drops from 80 candelas/m2 to a level
of around 2 candelas/m2.15 The effect of this wavelength
on the melanopsin containing retinal ganglion cells
responsible for circadian synthesis could suppress and
shorten melatonin onset and duration, and potentially
impact sleep, thermoregulation, blood pressure, and
glucose homeostasis.16,17
Sleep disturbance and intolerance to light appeared to
be the principal reasons given for withdrawal, especially
in older volunteers; in younger people withdrawal was
associated with lack of compliance with mask wear
and/or attendance. The level of light intolerance of 5–10%
appears acceptable as light therapy moves into efﬁcacy
trials. Further dose calibration experiments changing
intensity or with shorter duration may be justiﬁed
depending on future efﬁcacy trials.
The signiﬁcant withdrawal rate of 24% (11% in the ﬁrst
month of usage) and the self-reported adverse event rate
of ~ 75% all indicate that further modiﬁcations of mask
design are needed for home compliance to become
optimal. Patients with DME reported less adverse events
possibly due to higher motivation in participants with
treatable disease.
Neurobehavioural function as a measure of sleep
disturbance was reduced at month 3 in PVT-RT for both
age groups and PVT-NL for younger participants.
The delays in RT of 24.39 (younger) and 25.39 (older)
were within the SD of typical response times for healthy
non-sleep-deprived participants (40–100 ms) in our and
other published data.9,18 PVT-NL showed a larger 43%
mean change in younger participants but changed little in
older participants; impaired PVT-NL has been reported in
sleep-deprived young men but not older men.19,20
The worsening in NL returned to normal by month 4.
Although our results are generally reassuring we
believe that PVT is an important safety measurement and
should be included in dark adaptation blocking therapy
trials. Eight of our participants developed loss of
performance during the study (Supplementary Tables 3
and 4). NL rose as high as 40 in one participant and in 3
there was concordance between worsening NL and RT.
Worsening reaction times and NL have been observed
after extended periods of wakefulness21 and associated
with poor driving performance.22 We developed age-
speciﬁc upper criteria, extrapolated from published
normative data,7 useful in future clinical trials (o52 years:
NL= 17; 52–64 years: NL= 26; 464 years: NL= 31).
Some secondary outcomes (BCVA, OCT, mfERG
latency, and CCT deutan) showed statistically signiﬁcant
changes at month 3 but none were in an unsafe direction.
The GHQ12 evidence of worsening wellbeing is of
some concern. GHQ12 was a secondary outcome; so the
ﬁndings should be interpreted with caution but the
worsening was signiﬁcant in all the groups (28%
reduction for younger healthy controls) and some
participants moved from the no distress to the some
distress or severe distress categories. There were no
signiﬁcant changes in depressive symptoms on CESD.
We extended our safety study to a cohort of people
with DMO primarily to study safety but also to
investigate an effect on macular oedema. These
participants performed worse across all study variables
including daytime alertness, psychological wellbeing, and
retinal structure/function when compared with healthy
volunteers with similar ages (Group B). This is not
unexpected for retinal structure and function, especially
colour dysfunction23 but less familiar to ophthalmology
for poor wellbeing and alertness. Visually impaired
people have reported lowered alertness and performance
parameters24 and people with diabetes suppressed
neuropsychological test scores compared with age-
matched controls.25
All study parameters that measured retinal function
and structure improved by month 3 apart from EOG.
Improvements persisted into month 4 but only reached
statistical signiﬁcance for CS and MP1. The depression
scores improved but psychological wellbeing worsened at
month 3 as in the healthy cohort.
We detected a small beneﬁcial effect of mask wear on
DMO as measured by OCT. This effect was larger for
those with more severe thickness, may be clinically
relevant, was statistically signiﬁcant and comprised a 10–
20% reduction in thickness. Arden et al6 reported 6-month
OCT and BCVA changes in an uncontrolled patient
population with bilateral DMO where one eye was
treated with a light mask with four light-emitting diodes
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with similar parameters as in our OLED. The authors
reported a reduction in number of retinal cysts and
detected no adverse events, claiming the therapy to be
safe and acceptable. Their study had a number of
limitations in the post hoc statistical analysis and no safety
data were collected. However our results are consistent
with their ﬁndings. Faced with a global epidemic of
diabetes a readily available, inexpensive, non-invasive
home therapy that can be used at the earliest stages of
disease development, would be a major therapeutic asset.
Our study detected no major safety signal and allows a
move to phase 3 clinical trials of light therapy during
sleep for retinal diseases. Data from our DMO cohort
provide useful additional pilot evidence of a potential
beneﬁcial effect. We believe that the therapy will be
acceptable to most potential patients including older
people and people with diabetes. However it will be
challenging for some individuals, with a small but
acceptable proportion likely to be intolerant beyond a few
days. Including behavioural and psychological
investigations of the effect on sleep disturbance in future
clinical trials will be important including carefully
designed monitoring and exit criteria. Usefulness will
depend on improvements in mask design for compliance,
tolerability, and acceptability.
Summary
What was known before
K Light therapy has been proposed as a potential therapy for
retinal diseases.
K Dark adaptation during sleep increases oxygen demands
in the retina.
What this study adds
K Organic light-emitting diode sleep masks show no major
safety signal.
K Light therapy is acceptable apart from in some healthy
participants.
K Daytime alertness and psychological wellbeing should be
monitored during light therapy.
K Preliminary data suggest a beneﬁcial effect on diabetic
macular oedema.
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Safety and acceptability of an
organic light-emitting diode
sleep mask as a potential therapy
for retinal disease
To obtain credit, you should ﬁrst read the journal article.
After reading the article, you should be able to answer the
following, related, multiple choice questions. To complete
the questions (with a minimum 75% passing score) and earn
continuing medical education (CME) credit, please go to
www.medscape.org/journal/eye. Credit cannot be obtained
for tests completed on paper, although you may use the
worksheet below to keep a record of your answers.
You must be a registered user on Medscape.org. If you are
not registered on Medscape.org, please click on the new
users: Free Registration link on the left hand side of the
website to register.
Only one answer is correct for each question. Once you
successfully answer all post-test questions you will be able to
view and/or print your certiﬁcate. For questions regarding
the content of this activity, contact the accredited provider,
CME@medscape.net. For technical assistance, contact
CME@webmd.net.
American Medical Association's Physician's Recognition
Award (AMA PRA) credits are accepted in the US as
evidence of participation in CME activities. For further
information on this award, please refer to http://www.ama-
assn.org/ama/pub/about-ama/awards/ama-physicians-
recognition-award.page. The AMA has determined that
physicians not licensed in the US who participate in this
CME activity are eligible for AMA PRA Category 1 Creditst.
Through agreements that the AMA has made with agencies
in some countries, AMA PRA credit may be acceptable as
evidence of participation in CME activities. If you are not
licensed in the US, please complete the questions online,
print the AMA PRA CME credit certiﬁcate and present it to
your national medical association for review.
1. You are assessing a 63-year-old woman with diabetic macular
oedema, and you are considering treatment with an organic light-
emitting diode (OLED) at night to slow the progression of her
disease. Which of the following statements regarding the tolerability
of OLED therapy in the current study is most accurate?
A Only half of the cohort completed the study
B An estimated 90% of participants who dropped out did so in
the ﬁrst month
C Intolerance of light and sleep disturbance were the most
common reasons for study withdrawal
D Headaches were the most common reason for study
withdrawal
2. What were the effects of OLED therapy on attention tests in the
current study?
A No group experienced a difference in psychomotor vigilance
testing during or after treatment
B The cohort with diabetic macular oedema experienced an
improvement in psychomotor vigilance testing with treatment
C Response time decreased among young adults, and this
population continued to experience depression at 1 month
after OLED treatment
D OLED therapy slowed response times most among the cohort
with diabetic macular oedema
3. In the current study, which ophthalmologic outcome was most
improved with OLED therapy among adults with diabetic macular
oedema?
A Best corrected visual acuity
B Cambridge color vision test
C Optical coherence tomography mean central subﬁeld
thickness (CST)
D Electrooculogram
4. According to the results of the current study, what should you tell
this patient about OLED therapy and the risks for depression and
problems with sleep?
A OLED therapy signiﬁcantly improved depression overall
B OLED therapy signiﬁcantly worsened sleep quality overall
C There was no signiﬁcant change in depression or sleep scores
during treatment
D Depression scores worsened, but sleep quality improved
during treatment
Activity evaluation
1. The activity supported the learning objectives.
Strongly disagree Strongly agree
1 2 3 4 5
2. The material was organized clearly for learning to occur.
Strongly disagree Strongly agree
1 2 3 4 5
3. The content learned from this activity will impact my practice.
Strongly disagree Strongly agree
1 2 3 4 5
4. The activity was presented objectively and free of commercial
bias.
Strongly disagree Strongly agree
1 2 3 4 5
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